News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

University of California, San Diego (UCSD) Grants Aviva Systems Biology An Exclusive License To Commercialize Its GREMA Technology Which Maps And Analyzes The Interactive Behavior Of Gene Regulatory Elements

10/19/2005 5:12:36 PM

SAN DIEGO, Jan. 31 /PRNewswire/ -- Aviva Systems Biology, a biotechnology company dedicated to the development of novel platforms and solutions for the study of gene regulation, announced today that it has signed an agreement with the University of California, San Diego (UCSD) to exclusively license the rights to develop and commercialize technology for Gene Regulation Elements Mapping and Analysis (GREMA). GREMA technology was developed in the laboratory of Dr. Xiangdong Fu, a Professor in the Department of Cellular and Molecular Biology at the University of California, San Diego (UCSD). Dr. Fu is a leading researcher in the field of gene regulation and a participant in NIH's ENCODE Consortium. Mr. Julian Yuan, CEO of Aviva Systems Biology states, "We are delighted to collaborate with UCSD to develop and deliver this technology to researchers around the world."

GREMA technology is a sensitive method for the detection of virtually all DNA fragments, such as promoters, which interact with proteins. Using its core bioinformatics capabilities Aviva Systems Biology has identified approximately 32,000 potential promoter sequences; 20,000 of these promoters have been incorporated into a DNA microarray. GREMA technology is designed to capture enriched signal from genomic DNA that is bound to proteins. This signal is then very efficiently amplified in an unbiased manner and followed by signal quantification on a microarray.

This technology has many important applications useful for the understanding of transcription factor/DNA interactions: transcriptional regulation, mRNA splicing, DNA damage repair, gene deletion and duplication, and many others. Identification of disease specific transcription factor promoters and how their binding is altered during the course of disease could lead to the discovery of new specific drug targets.

Based in San Diego, California, Aviva Systems Biology is dedicated to the development of reagents for transcription factor research including antibodies to all putative transcription factors. Aviva Systems Biology also generates antibodies and additional reagents for other important research areas.

Contact Information: Cynthia Lane 11180 Roselle Street, Suite 300 San Diego, CA 92121 858-552-6979 X106

Aviva Systems Biology

CONTACT: Cynthia Lane of Aviva Systems Biology, +1-858-552-6979,ext. 106,

Read at

comments powered by Disqus